Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis

Patent metadata

Field	Value
Publication number	US-11219623-B2
Application number	US-201916361832-A
Country	US
Kind code	B2
Filing date	Mar 22, 2019
Priority date	Feb 26, 2015
Publication date	Jan 11, 2022
Grant date	Jan 11, 2022

Abstract

The present disclosure relates to modified nucleoside reverse transcriptase inhibitors (NRTIs), such asand compositions thereof, as well as methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to modified NRTIs, such asand compositions thereof, as well as methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.

First claim

What is claimed is:

1. A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis comprising administering to a subject having said condition a compound of formula I

wherein
R 1 is CH 3 or CH 2 CH 3 ; and
R 2 is H, CH 3 , or CH 2 CH 3 , provided that when R 2 is H, R 1 is not CH 3 .

2. The method of claim 1 , wherein R 2 is CH 3 or CH 2 CH 3 .

3. A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis comprising administering to a subject having said condition a compound having a structure selected from:

and pharmaceutically acceptable salts thereof.

4. The method of claim 3 , wherein the compound has a structure selected from:

and pharmaceutically acceptable salts thereof.

5. The method of claim 3 , wherein the compound has a structure selected from:

and pharmaceutically acceptable salts thereof.

6. The method of claim 3 , wherein the compound has a structure selected from:

7. The method of claim 1 , wherein the compound has the following structure:

8. The method of claim 1 , wherein the method comprises administering a composition comprising the compound of formula I and a pharmaceutically acceptable carrier.

9. The method of claim 1 , wherein the condition is Parkinson's disease.

10. The method of claim 1 , wherein the condition is Alzheimer's disease.

11. The method of claim 1 , wherein the condition is multiple sclerosis.

12. The method of claim 3 , wherein the method comprises administering a composition comprising the compound and a pharmaceutically acceptable carrier.

13. The method of claim 3 , wherein the condition is Parkinson's disease.

14. The method of claim 3 , wherein the condition is Alzheimer's disease.

15. The method of claim 3 , wherein the condition is multiple sclerosis.

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin
• Ambati Kameshwari

Classifications

• C07D411/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title